Xiaoting Yang

Xiaoting Yang

Auto-generated profile, based on publicly available information

Xiaoting Yang

Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Massimiliano RunfolaMassimiliano Runfola
Massimiliano Runfola
MPMichele Perni
Michele Perni
XYXiaoting Yang
Xiaoting Yang
MMMaria Marchese
Maria Marchese
ABAndrea Bacci
Andrea Bacci
Simona RapposelliSimona Rapposelli
Simona Rapposelli
The identification of effective pharmacological tools for Alzheimer’s disease (AD) represents one of the main challenges for therapeutic discovery. Due to the variety of pathological processes associated with AD, a promising route for pharmacological intervention involves the development of new chemical entities that can restore cellular homeostasis. To investigate this strategy, we designed and synthetized SG2, a compound related to the thyroid hormone thyroxine, that shares a pleiotropic activity with its endogenous parent compound, including autophagic flux promotion, neuroprotection, and metabolic reprogramming. We demonstrate herein that SG2 acts in a pleiotropic manner to induce recovery in a C. elegans model of AD based on the overexpression of Aβ42 and improves learning abilities in the 5XFAD mouse model of AD. Further, in vitro ADME-Tox profiling and toxicological studies in zebrafish confirmed the low toxicity of this compound, which represents a chemical starting point for AD drug development.